Trial Profile
A study of Radium-223 therapy in metastatic castration resistant prostate cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 24 Aug 2017 New trial record